Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Technology Stocks : U.S. Digital Communications (USDI) -- Ignore unavailable to you. Want to Upgrade?

To: BillRacer1 who wrote (165)	5/29/1998 11:34:00 PM
From: rbarsom	Respond to of 308

I think the Iridium beta trial tests are the big news here. It is just like most stocks they start out with news that people think is OK, but seems not that great when the stock does not double. Then the smart investors who do their homework and get in. Then the institutions. Then the brokers get behind it. Undervalued securities are what Wall Street is all about. ENMD was 12 dollars when the article in the New York Times came out it ran to 70. The news about the drug had been around for a while.